Cartesian Therapeutics (RNAC) Goodwill (2023 - 2026)

Cartesian Therapeutics (RNAC) has 4 years of Goodwill data on file, last reported at $48.2 million in Q1 2026.

• On a quarterly basis, Goodwill changed 0.0% year-over-year to $48.2 million in Q1 2026; TTM through Mar 2026 was $48.2 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $48.2 million, changed 0.0% from the prior year.
• Goodwill for Q1 2026 stood at $48.2 million, roughly flat from $48.2 million in the prior quarter.
• Over the last five years, Goodwill for RNAC reached as high as $48.2 million in Q4 2023 and fell as low as $48.2 million in Q4 2023.
• Historically, Goodwill has averaged $48.2 million across 4 years, with a median of $48.2 million in 2023.
• On a YoY basis, Goodwill climbed as much as 0.0% in 2024 and fell as far as 0.0% in 2024.
• Year by year, Goodwill stood at $48.2 million in 2023, then changed by 0.0% to $48.2 million in 2024, then changed by 0.0% to $48.2 million in 2025, then changed by 0.0% to $48.2 million in 2026.
• Per Business Quant data, the three most recent Goodwill figures were $48.2 million in Q1 2026, $48.2 million in Q4 2025, and $48.2 million in Q3 2025.